Magazine article Drug Topics

New Product Newswire

Magazine article Drug Topics

New Product Newswire

Article excerpt

Rx

NEW INDICATION

FDA approval for a new indication of Aciphex (rabeprazole) has been given to Eisai Inc., Teaneck, N.J., (201) 287-2000, and its comarketer, Janssen Pharmaceutica, Titusville, N.J., (800) JANSSEN. The proton pump inhibitor was approved in 1999 for shortterm (four to eight weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD), healing of duodenal ulcer, and treatment of pathological hypersecretory conditions. The new approval carries the indication for daytime and nighttime heartburn and other symptoms associated with GERD.

NEW ACQUISITIONS

Par Pharmaceuticals, Spring Valley, N.Y., (845) 425-- 7100, has acquired the U.S. rights to five Bristol-Myers Squibb products: Capoten (captopril) and Capozide (captopril and hydrochlorothiazide), antihypertensive drugs; the cholesterol-lowering Questran and Questran Light (cholestyramine); and Sumycin (tetracycline), an antibiotic.

NeoSan Pharmaceuticals, a business unit of Wilmington, N.C.-based aaiPharma Inc., (800) 575-- 4AAI, has entered into an agreement to purchase the U.S. rights to the Darvon (propoxyphene hydrochloride) and Darvocet (propoxyphene napsylate with acetaminophen) family of pain products from Eli Lilly.

NEW GENERICS

IVAX Corp., Miami, Fla., (305) 575-4105, and TEVA USA, North Wales, Pa., (888) TEVA USA, have been given the FDA's nod for the 5-, 10- and 15-mg strengths of buspirone hydrochloride tablets. The antianxiety agent, which provides a generic alternative to Bristol-Myers Squibb's BuSpar, is used in the management of general anxiety disorders or the short-term symptoms of anxiety.

Par Pharmaceutical has also received approval for three new strengths of buspirone: 5, 10, and 15 mg. Par is already marketing the 7.5-mg strength of the agent.

Newly approved for United Research Laboratories/Mutual Pharmaceutical Co. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.